Inovio Pharma (INO) – PRNewswire
-
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
-
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
-
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
-
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
INOVIO Reports Inducement Grant Under Inducement Plan
-
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
-
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
-
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
-
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
-
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
-
INOVIO Reports Inducement Grants Under Inducement Plan
-
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
-
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
-
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million
-
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
-
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
-
INOVIO Reports Inducement Grants Under Inducement Plan
-
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
-
INOVIO Reports Inducement Grants Under Inducement Plan
-
INOVIO to Present at the 2023 Jefferies Healthcare Conference
-
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
-
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
-
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
-
INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
-
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
-
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
-
European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107
-
Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023
-
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023
-
INOVIO Reports Inducement Grant Under Inducement Plan
-
INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights
-
INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
-
INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023
-
INOVIO Reports Inducement Grants Under Inducement Plan
-
INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
-
INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates
-
INOVIO Provides an Update on Lassa Fever and MERS Programs
-
INOVIO Reports Financial Results and Highlights for the Third Quarter 2022
-
INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
-
INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022
-
INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
-
INOVIO Reports Inducement Grants Under Inducement Plan
-
INOVIO to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
INOVIO Reports Financial Results and Highlights for the Second Quarter 2022
-
INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022
-
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients
Back to INO Stock Lookup
